ESTRO 2022 - Abstract Book

S1390

Abstract book

ESTRO 2022

any additional dose burden to the patient. CBCT images, routinely acquired for pre-treatment position verification, provide a daily representation of the patient anatomy but suffer from severe imaging artefacts preventing accurate dose calculations. Recently deep neural networks have shown promising results to correct CBCT images and generate high quality synthetic CTs (sCT), for proton dose calculations. Therefore, the aim of this study was to compare weekly rCT and daily sCT images of head and neck cancer patients to investigate the dosimetric accuracy of CBCT-based sCTs generated by a neural network. Materials and Methods A dataset of 30 head and neck cancer patients was utilized to generate synthetic CTs from daily pre-treatment patient alignment CBCTs using a previously developed and trained UNet deep convolutional neural network. Afterwards, clinically used proton treatment plans were recalculated on sCTs and weekly rCTs to evaluate the dosimetric accuracy of sCTs. Dose to clinical target volumes (CTV) and selected organs-at-risk (OAR) were compared between pCTs and both weekly rCTs and same-day sCTs by calculating mean dose differences. The investigated organs-at-risk include submandibular glands, pharyngeal constrictor muscles, parotid glands and the oral cavity. Results Figure 1 shows the mean relative dose differences between sCT/pCT and rCT/pCT pairs per ROI. The best agreement between pCT and rCT/sCT was observed for the low dose CTV (CTV 5425) with mean dose difference values of 0.3±0.2 % [0.18±0.15 Gy](rCT) versus 0.5±0.7 % [0.32±0.45 Gy](sCT), and for 0.2±0.2 % [0.13±0.11 Gy](rCT) versus 0.3±0.2 % [0.19±0.16 Gy](sCT) for the high dose CTV (CTV 7000). For all OARs, significantly larger dose differences were found than for the CTVs. The largest difference between sCT and pCT doses were observed in the left parotid gland with 14.7±16.4 % [1.61±1.31 Gy], compared to 8.4±9.2 % [1.01±0.87 Gy] between rCT and pCT, and in the left submandibular gland with 4.1±5.3 % [1.32±1.37 Gy](rCT) compared to 8.3±11.6 % [2.43±2.69 Gy](sCT). Overall, rCTs showed lower dose differences for all regions of interest. Figure 2 shows a comparison of daily sCT/pCT and weekly rCT/pCT dose differences for target volumes and OARs of the entire treatment of an exemplary patient.

Conclusion The deep learning based sCTs showed high agreement for target volume doses (<1%). However, larger dose differences were observed at OAR level. Further studies are required to investigate if these dose differences are clinically acceptable and if CBCT- based sCTs can fully substitute rCTs in the future.